Novonesis Explores Microbiome Supplements to Complement GLP-1 Weight-Loss Treatments
Novonesis CEO Ester Baiget suggests that dietary supplements, specifically microbiome-focused products, could serve as essential companions to the booming GLP-1 weight-loss drug market. During an interview on CNBC, Baiget highlighted ongoing studies involving a 'unique cocktail' of pro-, pre-, and post-biotics designed to help patients using medications like Wegovy and Ozempic feel better during treatment. The shift in consumer behavior is already evident; a PwC survey indicates that while GLP-1 users spend less on snacks, 40% are increasing their spending on vitamins and supplements. As the global dietary supplement market is projected to grow from $209.5 billion in 2025 to over $431.7 billion by 2033, companies like Novonesis aim to capitalize on this synergy between pharmaceutical intervention and nutritional support.
Topics: Biosolutions Dietary supplements GLP-1 medications Microbiome Weight loss drugs